Here's Why Moderna Shares Are Rising On Monday

Moderna Inc MRNA shares are trading higher by 18.9% at $164.27 after the company announced the first participant has been dosed in a clinical trial of an experimental HIV trimer mRNA vaccine.

According to Moderna, the primary hypothesis is that the soluble and membrane-bound HIV envelope trimer mRNA vaccines will be safe and well-tolerated by HIV-uninfected individuals and will elicit autologous neutralizing antibodies. Moderna says the trial is expected to enroll approximately 100 HIV-negative adults, aged 18 to 55 years.

See Also: Here's Why Affirm Raised Guidance Today

Moderna has a 52-week high of $497.49 and a 52-week low of $117.34.

Loading...
Loading...
MRNA Logo
MRNAModerna Inc
$26.40-1.34%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
6.18
Growth
Not Available
Quality
Not Available
Value
68.68
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In:
Comments
Loading...